ReviewFrontiers in cellular and infection microbiology2025
Pathogens that infect mammalian cells via sulfonated glycosaminoglycans.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Epidemiology, Phylogenetic Divergence, and Differential Pathogenicity of Feline RespiratoryTransboundary and emerging diseases · 2026Article
- Antiviral activity of natural and modified hydrocolloids: main sources, susceptible viruses, structure-activity relationship and mechanisms of action.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfonated glycosaminoglycans, such as heparan sulfate and dermatan sulfate, form major components of the cell surface and extracellular matrix, and display vital roles in mammalian physiology, including growth and development. The identification of specific binding to different glycosaminoglycans by a variety of pathogens has led to increased interest in this mechanism for understanding infection. Over the past four decades there have been more than 300 studies on various pathogens that utilize glycosaminoglycans in their infection process. Currently, no articles have collated all known pathogens that use this process. So it is timely that this article provides an overview of all known pathogens that use glycosaminoglycans to enhance their binding and/or infection in human cells. This was done by using the search terms "sulfate/sulphate" "pathogen", "virus", "bacteria", "parasite", "infection" and "glycosaminoglycans" to curate peer-reviewed and relevant original research articles from PubMed. This search found that glycosaminoglycans are used in the infection process for 59 viruses, 28 bacteria, and 8 other pathogens (i.e. parasitic protozoa, prions). These findings highlight the conserved and widespread use of glycosaminoglycans for enhancing pathogen infection. In addition, the curated list of pathogens in this study provides a resource for future studies to consider potential therapeutic approaches for targeted disruption of the interaction between pathogens and glycosaminoglycans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.